# HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

> **NCT06187961** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 44 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy (HAIC-FOLFOX)
- **DRUG:** Lenvatinib
- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT06187961
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-07
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- Akesobio

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06187961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06187961, "HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06187961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*